WO1999017623A1 - Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects - Google Patents

Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects Download PDF

Info

Publication number
WO1999017623A1
WO1999017623A1 PCT/IT1998/000249 IT9800249W WO9917623A1 WO 1999017623 A1 WO1999017623 A1 WO 1999017623A1 IT 9800249 W IT9800249 W IT 9800249W WO 9917623 A1 WO9917623 A1 WO 9917623A1
Authority
WO
WIPO (PCT)
Prior art keywords
carnitine
alcohol
composition
propionyl
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT1998/000249
Other languages
English (en)
French (fr)
Inventor
Aldo Fassi
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0004336A priority Critical patent/HUP0004336A3/hu
Priority to SK476-2000A priority patent/SK283384B6/sk
Priority to BR9812604-0A priority patent/BR9812604A/pt
Priority to PL98339621A priority patent/PL189663B1/pl
Priority to US09/509,652 priority patent/US6255346B1/en
Priority to UA2000041867A priority patent/UA66807C2/uk
Priority to EA200000377A priority patent/EA002177B1/ru
Priority to SI9830131T priority patent/SI1022960T1/xx
Priority to DK98946703T priority patent/DK1022960T3/da
Priority to EEP200000235A priority patent/EE04036B1/xx
Priority to HK00106847.2A priority patent/HK1028714B/en
Priority to AU93660/98A priority patent/AU730740B2/en
Priority to KR1020007003626A priority patent/KR100560097B1/ko
Priority to NZ503663A priority patent/NZ503663A/en
Priority to JP2000514534A priority patent/JP2001518484A/ja
Priority to AT98946703T priority patent/ATE220860T1/de
Priority to MXPA00003232A priority patent/MXPA00003232A/es
Priority to CA002305598A priority patent/CA2305598C/en
Priority to DE69806788T priority patent/DE69806788T2/de
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority to EP98946703A priority patent/EP1022960B1/en
Publication of WO1999017623A1 publication Critical patent/WO1999017623A1/en
Priority to IS5416A priority patent/IS2234B/is
Priority to NO20001688A priority patent/NO20001688L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a combination composition
  • withdrawal symptoms such as tremors, perspiration,
  • the drugs of choice are benzodiazepines such as
  • chlordiazepoxide or diazepam may become intoxicated and even
  • mice discloses that in mice "the addition of DL-carnitine to diet during
  • propionyl L-carnitine in the treatment of alcoholics, has never
  • L-carnitine comprising L-carnitine, acetyl L-carnitine, propionyl L-carnitine or
  • the withdrawal symptoms such as tremors, perspiration,
  • present invention may also be substantially healthy individuals,
  • compositions of the present invention can,
  • compositions may also comprise, in admixture with L-
  • ingredients such as dietary supplements, vitamins, co-enzymes,
  • compositions comprise 0.44 to
  • citrate particularly acid citrate; tartrate; phosphate, particularly
  • oxalate sulphate, particularly acid sulphate; trichloro acetate;
  • mice were divided into 4 groups of 5 rats each.
  • the first group (A) was administered saline solution
  • the third group (C) received LC (20 mg/kg), while
  • mice were divided into 4 groups of 10 rats each.
  • the first group (A) were administered saline solution (15).
  • MDA being a reliable and quantifiable index of the
  • composition of the present invention can be any composition of the present invention.
  • forms comprise oral unit dosage forms, both liquid and solid, such
  • diluents and excipients are used.
  • preservative, sweetening and flavouring agents can be added.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/IT1998/000249 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects Ceased WO1999017623A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
KR1020007003626A KR100560097B1 (ko) 1997-10-03 1998-09-18 알콜중독자에게는 알콜 금단(禁斷) 증상과 음주욕구를 억제하고, 그리고 건강한 사람에게는 과음을 예방하는 약제조성물
BR9812604-0A BR9812604A (pt) 1997-10-03 1998-09-18 Composição para suprimir os sintomas da retirada e do desejo insaciável pelo álcool em alcoólatras e para evitar o abuso do álcool em indivìduos saudáveis
PL98339621A PL189663B1 (pl) 1997-10-03 1998-09-18 Kompozycja i jej zastosowanie do łagodzenia objawów odstawienia alkoholu i głodu alkoholowego i do zapobiegania nadużywaniu alkoholu przez osoby zdrowe
US09/509,652 US6255346B1 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
UA2000041867A UA66807C2 (uk) 1997-10-03 1998-09-18 Композиція для подолання абстинентних симптомів та потягу до алкоголю в алкоголіків та запобігання зловживанням алкоголем у здорових осіб і спосіб її виготовлення (варіанти)
EA200000377A EA002177B1 (ru) 1997-10-03 1998-09-18 Композиция для подавления симптомов абстиненции и тяги к алкоголю у алкоголиков и профилактики злоупотребления алкоголем у здоровых людей
SI9830131T SI1022960T1 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
DK98946703T DK1022960T3 (da) 1997-10-03 1998-09-18 Præparat til undertrykkelse af abstinenssymptomer og trang til alkohol hos alkoholikere og forebyggelse af alkoholmisbrug hos raske personer
EEP200000235A EE04036B1 (et) 1997-10-03 1998-09-18 Kompositsioon alkoholi abstinentsisündroomi ja alkoholihimu mahasurumiseks alkohoolikutel ning alkoholi kuritarvitamise vältimiseks tervetel inimestel
HK00106847.2A HK1028714B (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
AU93660/98A AU730740B2 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
HU0004336A HUP0004336A3 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
NZ503663A NZ503663A (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
DE69806788T DE69806788T2 (de) 1997-10-03 1998-09-18 Zusammensetzung zur unterdrückung von entzugssymptomen und alkoholabhängigkeit bei alkoholikern sowie prävention von alkoholmissbrauch bei gesunden personen
AT98946703T ATE220860T1 (de) 1997-10-03 1998-09-18 Zusammensetzung zur unterdrückung von entzugssymptomen und alkoholabhängigkeit bei alkoholikern sowie prävention von alkoholmissbrauch bei gesunden personen
MXPA00003232A MXPA00003232A (es) 1997-10-03 1998-09-18 Composicion para suprimir sintomas de abandono y deseo de alcohol en alcoholicos e impedir el abuso de alcohol en sujetos saludables.
CA002305598A CA2305598C (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
JP2000514534A JP2001518484A (ja) 1997-10-03 1998-09-18 アルコール中毒者の禁断症状とアルコールに対する渇望を抑制するための、および、健康な人のアルコールの濫用を防ぐための組成物
SK476-2000A SK283384B6 (sk) 1997-10-03 1998-09-18 Orálne alebo parenterálne aplikovateľná kompozícia a jej použitie
EP98946703A EP1022960B1 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
IS5416A IS2234B (is) 1997-10-03 2000-03-24 Samsetning til að bæla fráhvarfseinkenni og fíkn í áfengi hjá áfengissjúklingum og fyrirbyggja misnotkun áfengis hjá heilbrigðum einstaklingum
NO20001688A NO20001688L (no) 1997-10-03 2000-03-31 Preparat for undertrykkelse av abstinenssymptomer og sug etter alkohol hos alkoholikere, og forebyggelse av misbruk av alkohol hos friske personer.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM97A000594 1997-10-03
IT97RM000594A IT1295408B1 (it) 1997-10-03 1997-10-03 Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo

Publications (1)

Publication Number Publication Date
WO1999017623A1 true WO1999017623A1 (en) 1999-04-15

Family

ID=11405277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1998/000249 Ceased WO1999017623A1 (en) 1997-10-03 1998-09-18 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects

Country Status (27)

Country Link
US (1) US6255346B1 (enExample)
EP (1) EP1022960B1 (enExample)
JP (1) JP2001518484A (enExample)
KR (2) KR100530368B1 (enExample)
CN (1) CN1092939C (enExample)
AT (1) ATE220860T1 (enExample)
AU (1) AU730740B2 (enExample)
BG (1) BG64363B1 (enExample)
BR (1) BR9812604A (enExample)
CA (1) CA2305598C (enExample)
CZ (1) CZ291801B6 (enExample)
DE (1) DE69806788T2 (enExample)
DK (1) DK1022960T3 (enExample)
EA (1) EA002177B1 (enExample)
EE (1) EE04036B1 (enExample)
ES (1) ES2180200T3 (enExample)
HU (1) HUP0004336A3 (enExample)
IS (1) IS2234B (enExample)
IT (1) IT1295408B1 (enExample)
MX (1) MXPA00003232A (enExample)
NO (1) NO20001688L (enExample)
NZ (1) NZ503663A (enExample)
PL (1) PL189663B1 (enExample)
PT (1) PT1022960E (enExample)
SK (1) SK283384B6 (enExample)
UA (1) UA66807C2 (enExample)
WO (1) WO1999017623A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007039A3 (en) * 1999-07-28 2001-03-29 Sigma Tau Healthscience Spa L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
EP1039894B1 (en) * 1997-12-01 2001-10-17 Sigma-Tau Healthscience S.p.A. Compositions for increasing the concentration and/or motility of spermatozoa in humans
WO2003084526A1 (en) * 2002-04-09 2003-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
US7776913B2 (en) 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
RU2300376C2 (ru) * 2005-05-11 2007-06-10 МУЗ Городская клиническая больница №3 им. М.А. Подгорбунского г.Кемерово Способ лечения при алкогольном делирии
CN101766715B (zh) * 2008-12-31 2012-08-29 克科 解酒醒酒组合物
CN101766637B (zh) * 2008-12-31 2012-08-29 克科 解酒醒酒组合物
CN101766716B (zh) * 2008-12-31 2012-08-29 克科 解酒醒酒组合物
CN101766717B (zh) * 2008-12-31 2012-10-10 克科 解酒醒酒组合物
CN101766635B (zh) * 2008-12-31 2012-10-10 克科 解酒醒酒组合物
CN101766672B (zh) * 2008-12-31 2012-10-10 克科 解酒醒酒组合物
CN106176756A (zh) * 2015-04-30 2016-12-07 刘力 包含手性异构化合物的赖氨酸五维药物组合物及其用途
WO2021211540A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Diagnosis and treatment of addiction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517125A1 (en) * 1991-06-05 1992-12-09 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of propionyl L-carnitine for regaining muscle tone in immobilised patients
DE19527281A1 (de) * 1995-07-26 1997-01-30 Hans Guenter Berner Gmbh Nahrungsergänzungsmittel
EP0793962A1 (en) * 1996-03-04 1997-09-10 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69618749D1 (de) * 1995-12-01 2002-03-14 Unilever Nv Mikrowellen erhitzbare knusperige Brötchen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517125A1 (en) * 1991-06-05 1992-12-09 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of propionyl L-carnitine for regaining muscle tone in immobilised patients
DE19527281A1 (de) * 1995-07-26 1997-01-30 Hans Guenter Berner Gmbh Nahrungsergänzungsmittel
EP0793962A1 (en) * 1996-03-04 1997-09-10 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABU MURAD C., ET AL.: "Hepatic triglyceride accumulation and the ethanol physical withdrawal syndrome in mice", BRITISH JOURNAL OF EXPERIMENTAL PETHOLOGY, vol. 58, no. 6, 1977, pages 606-615, XP002090918 *
CORBETT R. AND LEONARD B.E.: "Effects of carntine on changes caused by chronic administration of alcohol", NEUROPHARMACOLOGY, vol. 23, no. 2B, 1984, pages 269-271, XP002090919 *
LEIBOVITZ B ET AL: "Carnitine.", JOURNAL OF OPTIMAL NUTRITION, vol. 2, no. 2, 1993, pages 90 - 109, XP002090920 *
SCHMIDL M K ET AL: "MEDICAL FOODS", FOOD TECHNOLOGY, vol. 46, no. 4, April 1992 (1992-04-01), pages 87 - 96, XP002039690 *
TEMPESTA E., ET AL.: "Role of acetyl-L-carnitine in the treatment of cogntive deficit in chronic alcoholism", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, vol. 10, no. 1/2, 1990, pages 101-107, XP002090917 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039894B1 (en) * 1997-12-01 2001-10-17 Sigma-Tau Healthscience S.p.A. Compositions for increasing the concentration and/or motility of spermatozoa in humans
WO2001007039A3 (en) * 1999-07-28 2001-03-29 Sigma Tau Healthscience Spa L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
US6653349B1 (en) 1999-07-28 2003-11-25 Sigma-Tau Healthscience S.P.A. Composition for the prevention and treatment of kidney dysfunctions and diseases
AU779094B2 (en) * 1999-07-28 2005-01-06 Sigma Tau-Industrie Farmaceutiche Riunite S.P.A. Composition for the prevention and treatment of kidney dysfunctions and diseases
US7585896B2 (en) 1999-07-28 2009-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for the prevention and treatment of kidney dysfunctions and diseases
WO2003084526A1 (en) * 2002-04-09 2003-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
AU2003224443B2 (en) * 2002-04-09 2008-09-11 Alfasigma S.P.A. Combined use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
US8415392B2 (en) 2002-04-09 2013-04-09 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
US7776913B2 (en) 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause

Also Published As

Publication number Publication date
HUP0004336A3 (en) 2001-07-30
BG64363B1 (bg) 2004-12-30
DK1022960T3 (da) 2002-11-04
ITRM970594A1 (it) 1999-04-03
ES2180200T3 (es) 2003-02-01
EP1022960B1 (en) 2002-07-24
PT1022960E (pt) 2002-12-31
SK283384B6 (sk) 2003-06-03
NZ503663A (en) 2001-11-30
AU9366098A (en) 1999-04-27
IS5416A (is) 2000-03-24
EA002177B1 (ru) 2002-02-28
ATE220860T1 (de) 2002-08-15
PL189663B1 (pl) 2005-09-30
KR20050088499A (ko) 2005-09-06
KR20010030928A (ko) 2001-04-16
PL339621A1 (en) 2001-01-02
EE04036B1 (et) 2003-06-16
IS2234B (is) 2007-04-15
CN1092939C (zh) 2002-10-23
CA2305598A1 (en) 1999-04-15
EP1022960A1 (en) 2000-08-02
DE69806788T2 (de) 2003-04-03
EA200000377A1 (ru) 2000-10-30
AU730740B2 (en) 2001-03-15
IT1295408B1 (it) 1999-05-12
KR100530368B1 (ko) 2005-11-22
EE200000235A (et) 2001-06-15
SK4762000A3 (en) 2000-10-09
CZ20001207A3 (cs) 2000-11-15
BR9812604A (pt) 2000-08-01
CN1276704A (zh) 2000-12-13
CA2305598C (en) 2007-11-20
BG104286A (en) 2000-11-30
NO20001688L (no) 2000-06-02
NO20001688D0 (no) 2000-03-31
UA66807C2 (uk) 2004-06-15
KR100560097B1 (ko) 2006-03-13
HK1028714A1 (en) 2001-03-02
JP2001518484A (ja) 2001-10-16
CZ291801B6 (cs) 2003-05-14
US6255346B1 (en) 2001-07-03
MXPA00003232A (es) 2004-03-10
HUP0004336A2 (hu) 2001-05-28
DE69806788D1 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
AU730740B2 (en) Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
AU767492B2 (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
US20030206895A1 (en) Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
EP0007691B1 (en) Compositions for use in decreasing appetite for calories as carbohydrates
US20170042899A1 (en) Use of Tetrahydrobiopterine Derivatives in the Treatment and Nutrition of Patients With Amino Acid Metabolic Disorders
JP2009013143A (ja) 睡眠改善用組成物
JPH11180869A (ja) 血中脂質改善剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、飲食品および皮膚外用剤
CA2350220C (en) Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
HK1028714B (en) Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
KR20010021694A (ko) 스트레스 받는 자에 유용한 영양 조성물
EP0616805B1 (en) Use of acyl L-carnitine gamma-hydroxybutyrate for the treatment of alcoholism
JPH0198445A (ja) 経口摂食組成物
HK1009326B (en) Use of acyl l-carnitine gamma-hydroxybutyrate for the treatment of alcoholism
JP2005350420A (ja) 大腸癌予防剤及び該大腸癌予防剤を含有する飲食品
MXPA01004752A (en) Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
MXPA01003569A (es) Combinacion de carnitinas y resveratrol para prevenir o tratar enfermedades cerebrales y del envejecimiento
JPWO2001087291A1 (ja) 日内リズム正常化組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98810325.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998946703

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 93660/98

Country of ref document: AU

Ref document number: 503663

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2305598

Country of ref document: CA

Ref document number: 2305598

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4762000

Country of ref document: SK

Ref document number: PA/a/2000/003232

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2000-1207

Country of ref document: CZ

Ref document number: 1020007003626

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200000377

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09509652

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998946703

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-1207

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007003626

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 93660/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998946703

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2000-1207

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1020007003626

Country of ref document: KR